1N7.DU Stock Analysis
1N
Uncovered
Nevro Corp is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Nevro Corp. engages in the development of medical devices. The company is headquartered in Redwood City, California and currently employs 1,087 full-time employees. The company went IPO on 2014-11-06. The firm is focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The firm has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform, which is in addition to the Senza family of products. Its HFX solution delivers a versatile range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain based on what it believes to be the clinical evidence available. The firm's products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, Surpass Surgical Lead and Reduced-size Surpass-C Surgical Lead.